Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 15, 2007

Singulex Inks Separate Deals to Enhance the Clinical Utility of Biomarker Assays

  • Singulex reports two collaborations to advance biomarker assay development for use in R&D. The company is partnering with Washington University School of Medicine to increase the clinical utility of validated and recently discovered biomarkers. Separately, Singulex received a $900,000 phase 1/2 fast track SBIR contract from the NCI to develop assays to predict patient response to and efficacy of cancer drugs in development.

    In the first alliance, the aim is to develop biomarker assays in disease areas such as breast cancer, Alzheimer’s disease, diabetes, and stroke. Scientists at Washington University School of Medicine will join Singulex’ Erenna™ Technology Access Program. They will thus have access to Erenna, the company’s first biomarker detection platform.

    Under the NCI grant, Singulex will work with researchers at Washington Univ. and Sigma Aldrich to develop assays that measure the efficacy and patient response of anticancer drug candidates in the early stages of development. Singulex will use biological samples from the university and optimized reagents from Sigma Aldrich to develop assays to detect expression level changes for a panel of proteins associated with the growth of many cancers.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »